$204 MillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
-Total revenue in the last quarter.
-Net income is all revenues minus all expenses including taxes and interest in the last quarter.
$-2.84Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-3.11xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
-Earnings before interest expenses and taxes in the last quarter.
9The number of full time employees.
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechn...Benzinga, 4 months ago